• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Chimerix Inc (NQ: CMRX )

    0.9038 +0.0039 (+0.43%)
    Streaming Delayed Price Updated: 2:53 PM EDT, Jul 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 68,457
    Open 0.8950
    Bid (Size) 0.9000 (1)
    Ask (Size) 0.9076 (6)
    Prev. Close 0.8999
    Today's Range 0.8950 - 0.9212
    52wk Range 0.7800 - 1.300
    Shares Outstanding 86,249,744
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
    From Chimerix, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -5.85%
    -5.85%
    1 Month
    +1.55%
    +1.55%
    3 Month
    -1.11%
    -1.11%
    6 Month
    -2.82%
    -2.82%
    1 Year
    -22.75%
    -22.75%

    More News

    Read More
    CMRX Stock Earnings: Chimerix Misses EPS for Q1 2024
    Via InvestorPlace
    Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
    From Chimerix, Inc.
    Via GlobeNewswire
    Earnings Scheduled For February 29, 2024
    Via Benzinga
    Preview: Chimerix's Earnings
    Via Benzinga
    Earnings Outlook For Chimerix
    Via Benzinga
    4 Analysts Have This to Say About Chimerix
    Via Benzinga
    Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Appoints Marc D. Kozin to Board of Directors
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Present at TD Cowen 44th Annual Health Care Conference
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Appoints Lisa Decker to Board of Directors
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023
    From Chimerix, Inc.
    Via GlobeNewswire
    NetSol Technologies And 2 Other Stocks Under $2 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Overview Of Value Stocks In The Healthcare Sector
    Via Benzinga
    Chimerix to Participate in Upcoming Investor Conferences
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
    From Chimerix, Inc.
    Via GlobeNewswire
    CMRX Stock Warning! Smart Biotech Investors Will Avoid Chimerix Like the Plague.
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.